Abstract In the present study, we questioned whether the cholesterol synthesis inhibitor lovastatin potentiates the cytotoxicity of chemotherapeutic agents in the primitive CD34 + subpopulation of acute myeloid leukemia (AML) cells. AML mononuclear cells (n=17) were sorted in CD34 + and CD34 − fractions and compared to normal CD34 +/− cells (n=7). The percentage of surviving cells upon exposure to lovastatin (25-100 μM) and/or chemotherapeutics (cytarabin or daunorubicin) was determined with a luminescent cell viability assay. The results demonstrate that the primitive CD34 + subpopulation of normal and AML cells displayed a higher sensitivity to lovastatin than the more mature CD34
Introduction
Acute myeloid leukemia (AML) is characterized by accumulation of immature myeloid cells in the bone marrow. These malignant cells are usually hierarchically structured, similar to the normal hematopoietic system. We have reported that, according to this hierarchal structure, ATP-binding cassette (ABC) transporters are expressed in a differentiation-dependent manner [1] . Specifically, in primitive CD34 + CD38 − cells, a high expression of a number of more differentiated CD34 + CD38 + cells. Notably, in the leukemic counterpart, a much more heterogeneous pattern of ABC transporter gene expression was observed [1] . Recently, de Grouw et al. [2] published expression data for all 45 ABC transporters in AML cells. They found 22 ABC transporters to be lower expressed in the CD34 + CD38 + subpopulation compared to the CD34 + CD38
− subpopulation. In addition to the two major cholesterol efflux transporters (ABCA1 and ABCG1), two genes critical in cholesterol metabolism (3-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase and low-density lipoprotein receptor (LDLR)) were highly expressed in normal CD34 + CD38 − cells, indicative for an active cholesterol metabolism [1, 3] . In AML cells, an aberrant cellular cholesterol metabolism has been demonstrated, including a higher LDLR activity [4] . Interestingly, it was recently shown in vitro that cells isolated from a subgroup of AML patients demonstrated in their leukemic cells "an acute cholesterol response", i.e., a rapid increase in cellular cholesterol content in response to cytotoxic agents [5] . These AML cells were further characterized by an increased chemosensitivity upon blocking this acute cholesterol response by pretreatment of cells with a statin [4] . Statins act as competitive inhibitors of the enzyme HMGCoA reductase and hence block cellular cholesterol synthesis. Consequently, a role for these cholesterol synthesis inhibitors to improve standard antileukemic treatment has been suggested [4, [6] [7] [8] [9] [10] . In the present study, we focused on a subpopulation of AML cells (CD34 + ), i.e., cells that have more in common with the more primitive leukemic progenitor/stem cell compartment [11] , and questioned whether this subpopulation of cells is especially prone for the effects of lovastatin and chemotherapeutic agents. Our data demonstrate a higher sensitivity of the primitive CD34 + subpopulation for lovastatin compared to the more mature CD34
− subpopulation of normal as well as AML cells. Heterogeneity of the response observed in AML patients allowed identification of a subgroup with poor prognosis. [12] . Mononuclear cells were enriched by FicollIsopaque (Nycomed, Oslo, Norway) density gradient centrifugation and cryopreserved in RPMI 1640 medium (BioWhittaker, Brussels, Belgium) supplemented with 20% fetal calf serum (FCS; Hyclone, Logan, UT, USA) and 20% dimethyl sulfoxide (Merck, Amsterdam, The Netherlands) and stored at −196°C as described [13] .
Materials and methods

Normal
Materials
Mevinolin (L-154, 803-00G17) in the lactone form was obtained from Merck, Sharp & Dohme Research Laboratories (Rahway, NJ, USA), converted to its sodium salt, and a stock solution of mevinolin (lovastatin) at a concentration of 4 mg/mL was prepared as previously described. The cytotoxic agents daunorubicin (Aventis Pharma BV, Hoevelaken, The Netherlands) and cytarabin (Mayne Pharma (Benelux) SA-NV, Brussels, Belgium) were used.
Flow cytometric sorting
The normal and AML samples were incubated with a fluorescein isothiocyanate-conjugated antibody against CD34 (Becton Dickinson, San Jose, CA, USA) and a phycoerytrin-conjugated antibody against CD14 and CD15 or CD38. Sorting was performed using a MoFlo flow cytometer. Erythrocytes and quantitative polymerase chain reaction were performed as described before [13] .
Colony-forming cell assay 10 3 normal or AML CD34 + cells were sorted into Iscove's Modified Dulbecco's Media (IMDM) containing 10% FCS, 20 ng/mL interleukin-3 (IL-3), 100 ng/mL c-Kit ligand, 100 ng/mL Flt-3 ligand, and 100 ng/mL thrombopoietin as described. Twenty-four hours after treatment with different concentrations lovastatin, cytarabin, and daunorubicin, cells were plated into MethoCult H4230 (StemCell Technologies, Vancouver, Canada) supplemented with 20% IMDM, 20 ng/mL IL-3, 20 ng/mL G-CSF, 20 ng/mL IL-6, 20 ng/mL cKit ligand, and 1 U/mL EPO (Cilag: Eprex, Brussels, Belgium).
Statistical analysis
Friedman's and Mann-Whitney's nonparametric tests were performed to calculate significant differences, p values of <0.05. SPSS 14.0 statistical software [14] was used to analyze the data. Additionally, we looked for additive and synergistic effects of the combination treatment of lovastatin and chemotherapeutics. Additivity was defined as an increased inhibitory effect on cell survival of the combination exposure compared to the single exposure of lovastatin or chemotherapeutics. Synergism was defined by two individual agents (lovastatin and chemotherapeutics) acting together and creating an inhibitory effect on cell survival greater than predicted by knowing only the separate inhibitory effects of the individual agents.
Results
Patient characteristics
The AML patients (n=17) studied, median age of 51 (range 19-79), were classified according to the WHO classification: AML with cytogenetic abnormalities (n=5), AML with prior dysplastic syndrome (n=2), and the additional group consisting of M1 (n=4), M2 (n=3), and M4/M5 (n=3). The clinical and cellular characteristics of the patients are shown in Table 1 . The median peripheral blast cell count at diagnosis was 48.6×10 9 /L (range 2.2-200). The majority of the patients were treated according to ongoing HaematoOncology Co-operative Group (HOVON) protocols, i.e., the HOVON Swiss Group for Clinical Cancer Research AML-42 study for patients <60 years [15] and the HOVON 43 study for patients >60 years [16] . Palliative treatment was given to patients that were ineligible for intensive chemotherapy (n=2). These patients were treated with 6-mercaptopurine [17] . Eleven patients reached complete remission (CR) on protocol. In six patients, CR was not attained due to progression (n=2) or to treatment related toxicity (n=4). The median event-free survival (EFS) of all patients attaining CR was 13 months (range 1-37).
The CD34 + subpopulation of normal and AML hematopoietic cells is more sensitive to lovastatin treatment than the more mature CD34
− subpopulation
To evaluate whether differences exist in statin sensitivity between primitive and more differentiated cells, normal CD34 + and CD34 A similar experimental setup was used for the AMLs (n=17). From the total AML cell fraction, the CD34 + subfraction was separated from the CD34 − fraction by
MoFlo. The percentage of CD34 + cells varied strongly between the different AML samples as depicted in Table 1 (median 41% (range 7-92%)). Subsequently, the CD34 + and CD34
− fractions were exposed to varying concentrations of lovastatin (25-100 μM) for 20 h and the effects on cell survival were assessed. As depicted in Fig. 1b (Fig. 3b) .
The combination of lovastatin and chemotherapeutics potentiates cell death To evaluate whether the cytotoxic effects of two frequently used cytostatic agents, cytarabin and daunorubicin, might be promoted by cotreatment with lovastatin, the AML CD34 + and CD34
− subfractions were incubated with varying concentrations of lovastatin (25, 50, and 100 μM) in the presence or absence of varying concentrations of daunorubicin (0.01-0.5 μM) or cytarabin (0.0001-0.1 mg/mL) for 24 h. A dose-dependent decrease in cell survival was seen as depicted in Fig. 2 , which was augmented by lovastatin treatment. A median survival reduction of 21% (range minus 28-64%) was accomplished by exposing the AML CD34 + cells to 0.1 μM daunorubicin, which was 43% (range minus 56-78%) when the CD34 + AML cells were exposed to the combination of daunorubicin and 25 μM lovastatin (Fig. 2a) .
The combined use was slightly more effective in the CD34 + subpopulation compared to the CD34 − subpopulation ( Fig. 2b ; median 43% versus 36%) but the difference did not reach statistical significance. Comparable results were obtained for cytarabin (data not shown). However, also here within the group of AMLs, different subgroups could be distinguished when looking at cell survival. Most AML CD34 + cells with a reduced statin sensitivity demonstrated also a diminished susceptibility for the combined use of statins plus cytarabin or daunorubicin (Fig. 3) . To investigate whether the observed effects were also noticed in the most primitive AML cell population, AML CD34 + cells were sorted into the CD34 + CD38 − cell fraction and the CD34 + CD38 + fraction (n=7). Four AML samples belonged to the normal responder group and three samples to the abnormal responder group. As depicted in Fig. 4 (n=5) showed an inhibition of 12% and 8% with 25 μM lovastatin or daunorubicin, respectively, which increased to 36% inhibition when both agents were used (p = 0.01, data not shown). Comparable results were obtained cytarabin (28% versus 60%, p=0.04).
Given the observed variability in effects of lovastatin on the CD34 + AML cells, we questioned whether this might be explained by a difference in expression or modulation of downstream targets. Therefore, the ABCG1 and ABCA1 mRNA expression levels were studied both in the normal responder and abnormal responder AML group and compared to normal CD34 + cells. A nonsignificant higher ABCG1 mRNA expression was observed in the normal responder AML group compared to the abnormal responder AML group and normal CD34 + cells. In addition, the lovastatin-induced ABCG1 mRNA expression was studied in the different groups. No statistically significant difference was found between normal CD34 + cells (0.4 fold downregulation, range 0.29-0.36) versus the normal and abnormal AML responder group, 0.2 (range minus 0.16-0.53), and 0.5 fold (range 0.16-0.70) downregulation, respectively.
In vitro response pattern and clinical outcome
In view of the observed in vitro difference for statin sensitivity, we questioned whether these findings might correspond to patient characteristics or patient outcome. In the AML responder group, a normal or favorable cytogenetic pattern was found in 100% of the patients, while in the abnormal responder group, an unfavorable cytogenetic + and CD34 − normal (a; n=7) and AML cells (b; n=17) upon incubation with increasing lovastatin concentrations (25-100 μM). SEM are indicated pattern was present in 50% of the patients. In the responder group, the median peripheral blast cell count at presentation was 16.6×10 9 /L (range 2.2-128.3) and in the abnormal responder group was 81.4×10 9 /L (range 48.6-200, p= 0.02). Based on these factors, three prognostic risk groups can be defined, i.e., favorable risk (favorable cytogenetics in combination with a peripheral blood blast cell count <20×10 9 /L at diagnosis), poor risk (those with poor-risk cytogenetics), and intermediate risk group (all others) [18, 19] . In the responder group, 100% of the patients belonged to the good or intermediate risk group while in the abnormal responder group, this value was only 50% (Table 1) . These findings correlated with treatment results. Complete remission on intensive chemotherapy was attained in 91% of the patients in the AML normal responder group with an EFS of 12.5 months (range 1-37). In the abnormal responders, CR was attained in 17% of the patients with a EFS of 0 month (range 0-15).
Discussion
In the present study, we analyzed the in vitro effect of lovastatin on the survival of AML subpopulations in the absence or presence of conventional applied chemotherapeutics. So far, in vitro studies on statins in AML have been focused on the total AML cell population [6] [7] [8] [9] . However, information of well-defined subpopulations + AML cells that are responsible for the ongoing in vivo propagation [19, 20] . By studying two different subpopulations of AML cells (primitive CD34 + cells and more mature CD34
− cells), we were able to demonstrate a significant difference in lovastatin susceptibility. The inhibitory effects of lovastatin were especially observed on the primitive CD34 + subpopulation. The effects on the more mature CD34 − subpopulation were less pronounced, suggesting that the primitive cell fraction is more dependent on cholesterol synthesis, which is in line with the high expression of ABC transporters in these cells. In addition, there were increased although variable inhibitory effects by the combined use of lovastatin and cytotoxic agents in both the AML and normal CD34 + cells. Interestingly, we found that some AML CD34 + cells followed a response pattern similar to normal CD34 + cells while 35% of the AML CD34 + cells showed no change. This could not be reversed in a number of cases by co-exposure the cells to chemotherapeutic agents. Interestingly, the distinction between normal and abnormal responders for the AML CD34 + fraction was most pronounced in the CD34 + CD38 − cell fraction, a population that is enriched for leukemic stem cells [21] . The difference in responsiveness between the normal-and abnormal-responder AML groups could not be explained by a difference in the percentage of AML CD34 + cells. In addition, no difference in susceptibility for lovastatin-mediated upregulation of ABCG1 mRNA was observed which is a major downstream target of lovastatin. It is more conceivable that the difference is linked to additional cellular characteristics of the AML cells belonging to both groups. Patient characteristics demonstrated that the abnormal responder group had a significant higher peripheral blast cell count at presentation. Moreover, the group was characterized by a high frequency of poor-risk cytogenetic abnormalities. The cause of the difference in susceptibility is not resolved but might be linked to differences in the farnesylation or geranylgeranylation pathways that are also affected by lovastatin [3, 6] . It has been demonstrated that statins disrupt the localization and function of isoprenylated molecules in the cell membrane [3, 6] . This change will result in an altered GTPase function of the Ras or Rho signaling that has an important impact on cellular processes such as proliferation and survival [22, 23] . Alternatively, the difference may be linked to an altered expression of anti-apoptotic proteins between both AML groups. It has been described that overexpression of Bcl-xL protects against statin-induced apoptosis in murine [24] . Both of these possible explanations are currently under evaluation.
In summary, these results demonstrate distinct differences in lovastatin susceptibility between CD34 + and CD34 − in the normal and leukemic counterpart and between different AML subtypes. Additional studies will clarify whether the described in vitro assay can be used for in vivo identification of patients that might benefit from application of statins in combination with chemotherapeutic agents.
